Ronnie Morris, MD, Chief Executive Officer
Ronnie Morris, MD, serves as Champion Oncology CEO and was most recently one of the founders of MDVIP, the national leader in personalized healthcare. Serving as a board member, medical director and part of the executive management team, Dr. Morris helped build and manage MDVIP, a company that grew to a network of 400 doctors within 29 states servicing 125,000 consumers/patients. In December 2009, MDVIP was acquired by the Procter and Gamble Co. Prior to MDVIP, Dr. Morris was the chief medical officer and executive VP of AllianceCare, a 1500-plus-employee company that provided home healthcare, physical therapy and doctor visits for homebound patients.
At AllianceCare, Dr. Morris developed and operated the physician house call division of the business, and he was the general medical director for the company. He was the managing partner of a large multispecialty group that was acquired in 1998 by ProMedCo. Dr. Morris is a board-certified internist and until 2004, he had a private practice in Boca Raton, Florida. He has been a consultant for many pharmaceutical companies, including Pfizer, Merck and AstraZeneca.
Philip Breitfeld, MD, Chief Strategy and Innovation Officer
Philip Breitfeld, MD has more than 30 years of experience in oncology and was most recently Global Vice President at Quintiles, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at Quintiles where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior clinical development positions at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst, where he led oncology development and was Associate Chief Medical Officer.
Prior to his career in industry, he held academic positions at Harvard, University of Massachusetts, Indiana University, and Duke. He has approximately 50 publications in the literature dealing with basic cell and molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. Dr. Breitfeld is also a Director on the Company’s Board of Directors.
Bruce Ruggeri, PhD, Chief Scientific Officer
Bruce Ruggeri, PhD joined Champions Oncology in September 2018. Bruce has worked in basic and applied oncology and tumor biology research for 30 years in both academic and pharmaceutical industrial settings. Prior to joining Champions, Bruce held an academic teaching and research appointment for five years as Associate Professor in the Dept of Pathology and Experimental Medicine at Hahnemann University in Philadelphia before joining the pharmaceutical industry in 1997. During his tenure in pharma, Bruce worked on target-directed small molecule oncology drug discovery and translational pharmacology support through early clinical development across more than a dozen drug discovery programs while at Cephalon (1997- 2011), Teva Pharmaceuticals (2011-2014), and most recently, Incyte Corporation (2015-2018) where he was Executive Director of Pharmacology. In the course of his pharmaceutical career Bruce has worked with and managed multi-disciplinary teams within oncology drug discovery, has been actively engaged in oversight and management of research collaborations with numerous academic centers and industrial partners, and directed new target discovery and validation efforts in R&D. During his tenure in pharma, Bruce worked directly with Champions Oncology for 9 years, utilizing our extensive PDX portfolio and bioinformatics data platform to guide and support late drug discovery and early clinical development pharmacology studies in support of novel targeted therapeutic agents in 10 distinct drug discovery programs. Bruce has co-authored 98 peer-reviewed publications, holds 8 patents, and serves as Editorial Board member for Biochemical Pharmacology and Section Editor for Current Protocols in Pharmacology. Bruce is a member of American Association for Cancer Research and the American Society for Clinical Oncology, and serves as a consultant for Esanik Therapeutics LLC, Oncopia LLC, and Tyra Pharma Biosciences.
Dr. Ruggeri holds a B.S from LaSalle University, an M.S from the University of Delaware, and PhD from the University of Pennsylvania. He completed his Post-doctoral training in experimental and molecular pathology at the Fox Chase Cancer Center.
David Miller, MBA, Chief Financial Officer
David Miller serves as the chief financial officer at Champions Oncology, Inc. Mr. Miller served as vice president of finance and Operations at DMCWW, LLC. From January 2006 to March 2010, he served as the chief financial officer of NAF Funding, LLC. From January 2000 to December 2005, he served as vice president of finance and Operations at IDT Corp., where he led the creation and growth of the consumer phone services division to over one million customers of local and long distance service. From 1997 to 1999, he served as an assistant vice president of the internal audit department at Deutche Bank. He also held senior accountant positions at Schonbraun, Safris, Sternlieb, LLC and Margolin, Winer and Evans. He is a Certified Public Accountant. He holds a B.S. from Yeshiva University in 1991 and an MBA from Fordham in 1999.
Michael Ritchie, PhD, MBA, Vice President of Business Development
Michael Ritchie, PhD, MBA joined Champions Oncology in July of 2014 and currently serves as Vice President of Business Development, overseeing all aspects of commercial development, sales and marketing. Prior to joining Champions, he worked in the oncology research unit at Pfizer, managing therapeutic development programs in the antibody drug conjugate space and developing novel therapeutic antibody programs. Dr. Ritchie received an MBA from New York University, a doctorate in biochemistry from Temple University School of Medicine, and served a postdoctoral fellowship in Neuroscience at Harvard Medical School.
Maria Mancini, PhD, Vice President, Pharmacology
Maria Mancini, PhD, joined Champions in March of 2015 and serves as Vice President of Pharmacology overseeing the scientific operations of pharmacology research initiatives including pre-clinical, co-clinical and CLIA approved drug sensitivity testing. She previously served as the Director of Research for Biomodels LLC leading efforts to generate translational in vivo platforms to test the efficacy of agents developed to treat cancer and cancer regimen-related toxicities. Dr. Mancini received her PhD in Biochemistry and Molecular Genetics from the University of Maine and served a Postdoctoral fellowship in Oncology at Harvard Medical School in the laboratory of Dr. Alex Toker.
David DeOrnellis, BS, RLATG, CPIA, CMAR, Vice President, Global Laboratory Operations
David DeOrnellis joined Champions Oncology in June 2015 and serves as Vice President of Global Laboratory Operations, overseeing all aspects of the in vivo program, the Quality Management System, and regulatory compliance. Mr. DeOrnellis has twenty years of experience in biomedical research. Most recently, he served as Global Director of Quality Assurance at Harlan Laboratories, where he was responsible for the Quality Management System and Training Program for nineteen sites in eight countries. Immediately prior, he was the Associate Director of Technical Services at Novartis Institutes for BioMedical Research where he implemented a Technical Services team to provide in vivo study and surgical support, training, and colony management to meet the research needs for two Novartis divisions. Mr. DeOrnellis holds a BS from Arizona State University and maintains certifications through AALAS, PRIM&R, and ASQ.